ACADEMIA
Oita University Completes Dosing of Replicon RNA Vaccine in PI, Eyes Global PII/III
Oita University has completed administering its replicon RNA vaccine for COVID-19 to all subjects in a PI clinical trial underway since October last year. It is considering including not only Japan but also other countries for the ensuing PII/III trial…
To read the full story
Related Article
- Oita University to Begin PI Study for Replicon RNA Vaccine in October
September 10, 2021
ACADEMIA
- Urine-Derived Stem Cells Eyed as New Drug Discovery Tool
June 10, 2026
- Japan Cancer Center Lowers Recommended BMI Ceiling for Men to 25
June 5, 2026
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
- Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





